


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented): A compound of formula I



(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]-urea,

in which

D denotes a mono- or bicyclic aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR<sup>2</sup>, N(R<sup>2</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>2</sup>, CON(R<sup>2</sup>)<sub>2</sub> or -C≡CH,  
X denotes NR<sup>3</sup> or O,  
Y denotes O, S, NH, N-CN or N-NO<sub>2</sub>,  
R<sup>1</sup> denotes H, Ar, Het, or cycloalkyl,  
R<sup>1</sup> may also be A which is optionally mono-, di- or trisubstituted by OR<sup>2</sup>, SR<sup>2</sup>, S(O)<sub>m</sub>R<sup>2</sup>, SO<sub>2</sub>N(R<sup>2</sup>)<sub>2</sub>, SO<sub>3</sub>R<sup>2</sup>, S(=O)(=NR<sup>2</sup>)R<sup>2</sup>, NR<sup>2</sup>SO<sub>2</sub>R<sup>2</sup>, OSO<sub>2</sub>R<sup>2</sup>, OSO<sub>2</sub>N(R<sup>2</sup>)<sub>2</sub>, N(R<sup>2</sup>)<sub>2</sub>, CN, COOR<sup>2</sup>, CON(R<sup>2</sup>)<sub>2</sub>, Ar, Het or cycloalkyl,  
E denotes CH,  
Z is ethylene,  
Z' is ethylene,  
Q is absent or denotes O, NR<sup>2</sup>, C=O, SO<sub>2</sub> or C(R<sup>2</sup>)<sub>n</sub>,  
R<sup>2</sup> denotes H, A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Ar', -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Het', -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-cycloalkyl, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub> or -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-OR<sup>3</sup>,  
R<sup>3</sup> denotes H or A,

$R^4$ ,  $R^{4'}$  each, independently of one another, is absent or denote A, OH or OA, or  $R^4$  and  $R^{4'}$  together denote methylene or ethylene,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by =O, =S, =NH, =NR<sup>3</sup>, =NOR<sup>3</sup>, =NCOR<sup>3</sup>, =NCOOR<sup>3</sup>, =NOCOR<sup>3</sup>, R<sup>3</sup>, Hal, A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Ar, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Het, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-cycloalkyl, OR<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>COA, NR<sup>3</sup>CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>SO<sub>2</sub>A, COR<sup>3</sup>, SO<sub>2</sub>NR<sup>2</sup> and/or S(O)<sub>n</sub>A,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH<sub>2</sub> groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>2</sup>, N(R<sup>2</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>2</sup>, CON(R<sup>2</sup>)<sub>2</sub>, NR<sup>2</sup>COA, NR<sup>2</sup>SO<sub>2</sub>A, COR<sup>2</sup>, SO<sub>2</sub>N(R<sup>2</sup>)<sub>2</sub>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>2</sup>, -O-[C(R<sup>3</sup>)<sub>2</sub>]<sub>o</sub>-COOR<sup>2</sup>, SO<sub>3</sub>H or S(O)<sub>n</sub>A,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>COA, NR<sup>3</sup>CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>SO<sub>2</sub>A, COR<sup>3</sup>, SO<sub>2</sub>N(R<sup>3</sup>)<sub>2</sub>, S(O)<sub>n</sub>A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>3</sup> or -O-[C(R<sup>3</sup>)<sub>2</sub>]<sub>o</sub>-COOR<sup>3</sup>,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen (=O), =S, =N(R<sup>2</sup>)<sub>2</sub>, Hal, A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Ar, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Het', -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-cycloalkyl, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-OR<sup>2</sup>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>2</sup>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-CON(R<sup>2</sup>)<sub>2</sub>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-NR<sup>2</sup>COA, NR<sup>2</sup>CON(R<sup>2</sup>)<sub>2</sub>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-NR<sup>2</sup>SO<sub>2</sub>A, COR<sup>2</sup>, SO<sub>2</sub>N(R<sup>2</sup>)<sub>2</sub> and/or S(O)<sub>n</sub>A,

Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, =N(R<sup>3</sup>)<sub>2</sub>, Hal, A, OR<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>COA, NR<sup>3</sup>CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>SO<sub>2</sub>A, COR<sup>3</sup>, SO<sub>2</sub>N(R<sup>3</sup>)<sub>2</sub> and/or S(O)<sub>n</sub>A,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2,

o denotes 1, 2 or 3, and

p denotes 1, 2, 3, 4 or 5,

or a pharmaceutically usable salt thereof, or a stereoisomer thereof, including mixtures thereof in all ratios.

2. (Previously Presented): A compound according to Claim 1, in which D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR<sup>2</sup> or COOR<sup>2</sup>, or pyridyl which is unsubstituted or monosubstituted by Hal.

3. (Previously Presented): A compound according to Claim 1, in which D denotes phenyl which is monosubstituted by Hal.

4. (Previously Presented): A compound according to Claim 1, in which R<sup>2</sup> denotes H or A.

5. (Previously Presented): A compound according to Claim 1, in which T denotes

a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), or

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OR<sup>2</sup> or NR<sup>2</sup>COA, or a monocyclic unsubstituted, saturated carbocycle.

6. (Previously Presented): A compound according to Claim 1, in which Q is absent or denotes O or CH<sub>2</sub>.

7. (Previously Presented): A compound according to Claim 1, in which Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>2</sup>, NR<sup>2</sup>COA, SO<sub>2</sub>A, SO<sub>2</sub>NH<sub>2</sub>, COOR<sup>2</sup> or CN.

8. (Previously Presented): A compound according to Claim 1, according to Claim 1 in which Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>3</sup> or NR<sup>3</sup>COA.

9. (Previously Presented): A compound according to Claim 1, in which R<sup>1</sup> denotes Ar, Het, cycloalkyl or A, which may be monosubstituted by OR<sup>2</sup>.

10. (Previously Presented): A compound according to Claim 1, in which R<sup>1</sup> denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA, a monocyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms, or A, which may be monosubstituted by OR<sup>3</sup>.

11. (Previously Presented): A compound according to Claim 1, in which Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O).

12. (Previously Presented): A compound according to Claim 1, in which Y denotes O.

13. (Previously Presented): A compound according to Claim 1, in which X denotes NR<sup>3</sup> or O, and R<sup>3</sup> denotes H.

14. (Cancelled):

15. (Previously Presented): A compound according to Claim 1, in which T denotes

a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle.

16. (Previously Presented): A compound according to Claim 1, in which A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F.

17. (Previously Presented): A compound according to Claim 1, in which

D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR<sup>2</sup> or COOR<sup>2</sup>, or pyridyl which is unsubstituted or monosubstituted by Hal,

X denotes NR<sup>3</sup> or O,

Y denotes O,

R<sup>1</sup> denotes Ar, Het, cycloalkyl or A, which may be monosubstituted by OR<sup>2</sup>,

E denotes CH,

Z, Z' each denote ethylene,

Q is absent or denotes O or CH<sub>2</sub>,

R<sup>2</sup> denotes H or A,

R<sup>3</sup> denotes H or A,

R<sup>4</sup>, R<sup>4'</sup> each, independently of one another, is absent or denote A, OH or OA, or R<sup>4</sup> and R<sup>4'</sup> together denote methylene or ethylene,

T denotes a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>2</sup>, NR<sup>2</sup>COA, SO<sub>2</sub>A, SO<sub>2</sub>NH<sub>2</sub>, COOR<sup>2</sup> or CN,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

Hal denotes F, Cl, Br or I, and

p denotes 1, 2, 3, 4 or 5.

18. (Previously Presented): A compound according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

X denotes NR<sup>3</sup> or O,

Y denotes O,

R<sup>1</sup> denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA, a monocyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms, or A, which may be monosubstituted by OR<sup>3</sup>,

R<sup>3</sup> denotes H,

E denotes CH,

Z, Z' each denote ethylene,

Q is absent or denotes O or CH<sub>2</sub>,

R<sup>2</sup> denotes H or A,

R<sup>3</sup> denotes H or A,

R<sup>4</sup>, R<sup>4</sup> each, independently of one another, is absent or denote A, OH or OA, or R<sup>4</sup> and R<sup>4</sup> together denote methylene or ethylene,

T denotes a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA,

or a monocyclic unsubstituted, saturated carbocycle,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and

Hal denotes F, Cl, Br or I.

19. (Previously Presented): A compound according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

X denotes NR<sup>3</sup> or O,

Y denotes O,

$R^1$  denotes thienyl, furyl, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA,  
or  
A, which may be monosubstituted by  $OR^3$ ,  
 $R^3$  denotes H or A,  
 $R^{3'}$  denotes H,  
E denotes CH,  
 $Z, Z'$  each denote ethylene,  
Q is absent or denotes O or  $CH_2$ ,  
 $R^2$  denotes H or A,  
 $R^3$  denotes H or A,  
 $R^4, R^4'$  each, independently of one another, is absent or denote A, OH or OA, or  $R^4$  and  $R^4'$  together denote methylene or ethylene,  
T denotes piperidinyl, piperazinyl, pyridinyl, 2-oxopiperidin-1-yl,  
2-oxopiperidin-4-yl, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, morpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxo-piperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, pyridazinyl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 6-oxopiperazin-1-yl, 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl, where the radicals may additionally be monosubstituted by A,  
phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA,  
or a monocyclic unsubstituted, saturated carbocycle,  
A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and  
Hal denotes F, Cl, Br or I.

20. (Previously Presented): A compound according to Claim 1, in which  
D denotes phenyl which is monosubstituted by Hal,

X denotes NR<sup>3</sup> or O,  
Y denotes O,  
R<sup>1</sup> denotes thienyl, furyl, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA,  
or  
A, which may be monosubstituted by OR<sup>3</sup>,  
R<sup>3</sup> denotes H or A,  
R<sup>3'</sup> denotes H,  
E denotes CH,  
Z denotes ethylene,  
Z' denotes ethylene,  
Q is absent or denotes O or CH<sub>2</sub>,  
R<sup>2</sup> denotes H or A,  
R<sup>3</sup> denotes H or A,  
R<sup>4</sup>, R<sup>4'</sup> is absent, or R<sup>4</sup> and R<sup>4'</sup> together denote methylene or ethylene,  
T denotes piperidin-1- or 4-yl, piperazinyl, morpholin-4-yl,  
each of which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O),  
or unsubstituted cyclohexyl,  
A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and  
Hal denotes F, Cl, Br or I.

21. (Previously Presented): A compound according to Claim 1, wherein said compound is selected from:

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidiny1-1-yl)-2-oxo-1-phenylethyl]-urea,  
(R)-1-(4-chlorophenyl)-3-{2-[4-(4-fluorophenoxy)piperidin-1-yl]-2-oxo-1-phenylethyl}urea ,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

(R,R)-1-(4-chlorophenyl)-3-{2-methoxy-1-[1-(1'-methyl-4,4'-bipiperidinyl-1-yl)-methanoyl]propyl}urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-hydroxy-4-(4-methoxyphenyl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea,

(R)-N-[4-(1-{2-[3-(4-chlorophenyl)ureido]-2-phenylethanoyl}piperidin-4-ylmethyl)-phenyl]acetamide,

(R)-1-(4-chlorophenyl)-3-{2-oxo-1-phenyl-2-[4-(1-phenylmethanoyl)piperidin-1-yl]-ethyl}urea,

(R,S)-1-[2-(3-benzylpiperidin-1-yl)-2-oxo-1-phenylethyl]-3-(4-chlorophenyl)urea,

(R,R)-1-(4-chlorophenyl)-3-(1-{1-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-methanoyl}-2-methoxypropyl)urea bistrifluoroacetate,

(R)-1-(2-4,4'-bipiperidinyl-1-yl-2-oxo-1-phenylethyl)-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-[2-4,4'-bipiperidinyl-1-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-(2-4,4'-bipiperidinyl-1-yl-2-oxo-1-thiophen-2-ylethyl)-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-(4-chlorophenyl)-3-[1-(4-hydroxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[1-(4-hydroxyphenyl)-2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxoethyl]urea trifluoroacetate,

1-[2-[1,4']bipiperidinyl-1'-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-3-(4-chlorophenyl)urea,

(R)-1-(4-chlorophenyl)-3-[2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-phenylethyl]urea trifluoroacetate,

(R)-1-(2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-phenylethyl)-3-(4-chlorophenyl)urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{1-(4-hydroxyphenyl)-2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxoethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-thiophen-2-ylethyl)-3-(4-chlorophenyl)urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-thiophen-2-ylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea,

(R)-1-(4-chlorophenyl)-3-[2-(4,4'-bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea,

(R)-1-(4-chlorophenyl)-3-[1-(2-chlorophenyl)-2-(1'-methyl-2'-oxo-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea,

(R)-1-(4-chlorophenyl)-3-[1-phenyl-2-(1'-methyl-2'-oxo-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea,

2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)-carbamate,

2-4,4'-bipiperidinyl-1-yl-1-(2-chlorophenyl)-2-oxoethyl (R)-(4-chlorophenyl)-carbamate hydrochloride,

2-4,4'-bipiperidinyl-1-yl-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate hydrochloride,

1-(2-chlorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,

1-(2-chlorophenyl)-2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,

2-[1,4']bipiperidinyl-1'-yl-1-(2-chlorophenyl)-2-oxoethyl (R)-(4-chlorophenyl)-carbamate trifluoroacetate,

2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)-carbamate trifluoroacetate,

2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,

1-(2-chlorophenyl)-2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxoethyl (R)-(4-chlorophenyl)carbamate bistrifluoroacetate,

2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate bistrifluoroacetate,

1-(2,3-difluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate,

1-(2-fluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate,

1-(2-methoxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.


22. (Previously Presented): A process for the preparation of a compound according to Claim 1, said process comprising

a) for the preparation of compounds


X denotes NH and

Y denotes O,

reacting a compound of formula II



with a compound of formula III



III,


or

b) for the preparation of compounds

in which


X and Y denote O,

reacting a compound of formula IV



IV,

with a compound of formula V



V

in which

X and Y denote O, and

L denotes Cl, Br, I or a free or reactively functionally modified OH group,

and/or a base or acid of formula I is converted into one of its salts.

23. (Previously Presented): A method of inhibiting coagulation factor Xa in a patient, comprising administering to said patient an effective amount of a compound of claim 1.

24. (Previously Presented): A method of inhibiting coagulation factor VIIa in a patient, comprising administering to said patient an effective amount of a compound of claim 1.

25. (Previously Presented): A pharmaceutical composition comprising a compound according to Claim 1, and one or more excipients and/or adjuvants.

26. (Previously Presented): A pharmaceutical composition comprising a compound according to Claim 1, and at least one further medicament active ingredient.

27. (Cancelled):

28. (Previously Presented): A kit comprising a first and second separate packs, said first pack containing an effective amount of a compound according to Claim 1, and said second pack containing an effective amount of a further medicament active ingredient.

29. (Cancelled):

30. (Previously Presented): A compound according to claim 1, wherein Q is absent.

31. (Previously Presented): A compound according to claim 30, wherein X is NR<sup>3</sup> and Y is O.

32. (Previously Presented): A compound according to claim 30, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O).

33. (Previously Presented): A compound according to claim 31, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen

(=O).

34. (Previously Presented): A compound according to claim 30, wherein R<sup>1</sup> is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, or OA.

35. (Previously Presented): A compound according to claim 33, wherein R<sup>1</sup> is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, or OA.

36. (Previously Presented): A compound according to claim 30, wherein D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, hydroxyl, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl.

37. (Previously Presented): A compound according to claim 35, wherein D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, hydroxyl, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl.

38. (Previously Presented): A method of treating a patient suffering from thrombosis comprising administering to said patient an effective amount of a compound according to claim 1.

39. (Cancelled):

40. (New): A compound according to claim 2, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O).

41. (New): A compound according to claim 40, wherein T is piperidinyl, 2-oxopiperidin-1-yl, or 2-oxopiperidin-4-yl, which in each case is optionally monosubstituted by A.